Previous 10 | Next 10 |
2023-08-14 05:10:00 ET Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to build an unstoppable stream of passive income. Many leading pharm...
2023-08-12 06:15:00 ET Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on. Three Motley Fool contributors identified stocks that should make income investors happy. Here's why they think AbbVie ...
2023-08-08 13:05:05 ET Summary Eli Lilly and Company's Q2 2023 earnings were boosted by strong sales growth of three key products in its pipeline: Verzenio, Jardiance, and Mounjaro. Verzenio, a breast cancer drug, saw significant sales growth due to its approval for multiple indic...
2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...
2023-08-03 08:28:46 ET More on Ionis, Novartis, etc. Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Ionis: Potential Advancement Into HAE Space Makes This A Must Watch Novartis Buys Chinook: M&...
2023-08-02 08:56:23 ET More on TG Therapeutics TG Therapeutics: The Hype Is Gone TG Therapeutics: Fairly Valued After Earnings Miss, EU Deal (Rating Upgrade) TG Therapeutics: Addressing The SC Ocrevus Concern TG Therapeutics falls as Roche succeeds in Phase 3...
2023-08-02 06:46:35 ET More on market strategy My Current View Of The S&P 500 Index: August 2023 Edition (Technical Analysis) Avi Gilburt Warns Of Potential Banking Crisis; Charts Indicate Major Disruptions Morgan Stanley bear Wilson sees a 2019-like rally this y...
2023-08-01 14:30:32 ET Amid an on-going shortage of the ADHD drug Adderall (mixed amphetamine salts), the US FDA and DEA are asking manufacturers to step up production. The nationwide shortage has been happening since at least October 2022 when the FDA issued an advisory , specifica...
2023-08-01 08:51:10 ET Chinook Therapeutics ( NASDAQ: KDNY ) rose almost 3% in premarket trading after the Hart-Scott Rodino antitrust waiting period for its planned sale to Novartis ( NYSE: NVS ) expired. The HSR wating period for the sale of Chinook ( KDNY ) ...
2023-07-31 18:17:01 ET Summary Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. The firm is a clinical stage biopharma developing immunotherapy treatments for solid tumor cancer conditions. Adlai Nortye is in Phase 3 trials...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...